Inotuzumab Ozogamicin clinical trials
Also written CMC-544, Besponsa and Way 207294.
How each study uses Inotuzumab Ozogamicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Inotuzumab Ozogamicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Aug 2017 · BESPONSA · BLA 761040 (FDA, Drugs@FDA)
- European Union
- 28 Jun 2017 · Besponsa · EMEA/H/C/004119 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
52 studies that test it; most in 2019 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 6 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 39
Pfizer (13) · M.D. Anderson Cancer Center (9) · Institute of Hematology & Blood Diseases Hospital, China (5) · Children's Oncology Group (2) · Alliance for Clinical Trials in Oncology (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Dana-Farber Cancer Institute (1) · University of Virginia (1)
Often tested with
Tested in the same studies.
Blinatumomab (10) · Venetoclax (4) · Vincristine (4) · Prednisone (4) · Cyclophosphamide (3) · Doxorubicin (2) · Mercaptopurine (2) · Rituximab (2)
Related medicines
As reviewed, each with the page that says it.
- One of Antibody-drug conjugates (ADCs) source
- One of Immunotoxins source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 1 in phase 3
Studies that test Inotuzumab Ozogamicin, phase 3 first.
- Nov 2027Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 3 · Alliance for Clinical Trials in Oncology
- Nov 2026Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaPhase 1/2 · Leland Metheny
- Nov 2026Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Dec 2026Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaPhase 2 · Children's Oncology Group
- Feb 2027Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaPhase 2 · National Cancer Institute (NCI)
- Feb 2027Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseasePhase 2 · M.D. Anderson Cancer Center
- Apr 2027Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic LeukemiaPhase 2 · Alliance for Clinical Trials in Oncology
- May 2027Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNot applicable · Institute of Hematology & Blood Diseases Hospital, China
Studies
Open first, then newest update. How each study uses Inotuzumab Ozogamicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 53
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as Inotuzumab OzogamicinHow we know
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)RecruitingPhase 1Sunil G. IyerNCT07936266Written as Inotuzumab ozogamicinHow we know
- Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLNot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07921550Written as Inotuzumab ozogamicin (INO)How we know
- Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingPhase 2PETHEMA FoundationNCT07862946Written as Inotuzumab Ozogamicin (IO)How we know
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Inotuzumab OzogamicinHow we know
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)RecruitingPhase 3Charite University, Berlin, GermanyNCT07476729Written as Inotuzumab ozogamicin (INO)How we know
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingPhase 2PfizerNCT05748171Written as Inotuzumab ozogamicinHow we know
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Inotuzumab ozogamicinHow we know
- Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaRecruitingPhase 1/2Leland MethenyNCT03104491Written as Inotuzumab OzogamicinHow we know
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Inotuzumab OzogamicinHow we know
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT01371630Written as Inotuzumab OzogamicinHow we know
- Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07643103Written as Inotuzumab Ozogamicin (IO)How we know
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingPhase 2University of ChicagoNCT04747912Written as Inotuzumab ozogamicinHow we know
- Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02877303Written as Inotuzumab OzogamicinHow we know
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06985485Written as Blinatumomab and Inotuzumab OzogamicinHow we know
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06387121Written as Inotuzumab ozogamicinHow we know
- Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALLRecruitingPhase 2Sheng-Li Xue, MDNCT05940961Written as Inotuzumab OzogamicinHow we know
- Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06554626Written as Inotuzumab ozogamicinHow we know
- Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06427330Written as Inotuzumab ozogamicinHow we know
- Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALLRecruitingPhase 2Nicola GoekbugetNCT03460522Written as Inotuzumab ozogamicinHow we know
See all 53 studies that test Inotuzumab Ozogamicin →
Given beside what is tested · 6 — Inotuzumab Ozogamicin is usual care or a partner of the new treatment
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2BeOne MedicinesNCT07770698Written as Inotuzumab ozogamicinHow we know
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07840976Written as Inotuzumab Ozogamicin (IO)How we know
- Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06287229Written as Inotuzumab OzogamicinHow we know
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07493161Written as Inotuzumab ozogamicinHow we know
- A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06087419Written as Inotuzumab OzogamicinHow we know
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationTerminatedPhase 2M.D. Anderson Cancer CenterNCT03856216Written as Inotuzumab OzogamicinHow we know
What changed recently
From the registry's own updates since Oct 21, 2026.
Started recruiting1
Newly registered2
Codes
What other systems call Inotuzumab Ozogamicin · ClinicalTrials.gg INT006842
- MeSH (NLM) D000080045Inotuzumab OzogamicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P93RUU11P7INOTUZUMAB OZOGAMICINConfirmed FDA, NLM, Wikidata
- RxNorm 1942950Confirmed FDA, Wikidata
- Wikidata Q3799041inotuzumab ozogamicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71542Inotuzumab OzogamicinOne source FDA
- DrugBank DB05889One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000080045 | Inotuzumab Ozogamicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P93RUU11P7 | INOTUZUMAB OZOGAMICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1942950 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3799041 | inotuzumab ozogamicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71542 | Inotuzumab Ozogamicin | One source FDA |
| DrugBank | DB05889 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.